Salazopyrin
In brief
- Salazopyrin (sulfasalazine) is usually dispensed from pharmacies; in most major markets it is prescription-only (Rx), though local availability and pharmacy policies vary and some pharmacies may supply it without a receipt — always check local regulations and pharmacy practice in Australia.
- Used for induction and maintenance of ulcerative colitis and for rheumatoid arthritis / juvenile idiopathic arthritis; salazopyrin is metabolised by gut bacteria to 5‑aminosalicylic acid (anti‑inflammatory) and sulfapyridine (antibacterial/immunomodulatory), and its benefit is from combined anti‑inflammatory and immunomodulatory effects.
- Typical dosages: ulcerative colitis adults 1–2 g/day initially (maintenance ~2 g/day, up to 4 g/day in severe disease); rheumatoid arthritis adults start ~0.5 g/day titrating to ~2 g/day (up to 3 g/day); children ≥6 years 30–50 mg/kg/day (usually up to 2 g/day); split into 2–4 doses.
- Available as oral tablets: immediate‑release 500 mg and delayed‑release (EN‑tabs) 500 mg; oral suspension exists in some regions but is uncommon.
- Onset of clinical benefit is not immediate: for ulcerative colitis some response can be seen over 3–6 weeks; for rheumatoid or juvenile arthritis improvement usually takes 6–12 weeks.
- Duration of action requires continuous daily dosing for maintained effect; treatment is often continued for months to years to prevent relapse and the therapeutic effect persists while therapy is continued.
- Avoid excessive alcohol — alcohol may increase risk of liver toxicity and worsen side effects; alcohol should be limited and use discussed with your prescriber.
- The most common side effect is gastrointestinal upset (nausea, vomiting, abdominal pain), with other frequent effects including headache, rash and reversible yellow‑orange discoloration of urine.
- Would you like to try salazopyrin without a prescription?
Basic Salazopyrin Information
- INN (International Nonproprietary Name): Sulfasalazine
- Brand Names Available In Australia: Azulfidine; Azulfidine EN-tabs; Salazopyrin; Salazopyrine; Sulfasalazin (Heumann) and multiple generics supplied by international manufacturers.
- ATC Code: A07EC01
- Forms & Dosages: Immediate‑release tablets 500 mg; Delayed‑release (EN) 500 mg enteric‑coated tablets.
- Manufacturers In Australia: International suppliers include Pfizer, Heumann Pharma, Actavis and a range of generic manufacturers.
- Registration Status In Australia: Registered and available in multiple markets including Australia; check ARTG for current product listings.
- OTC / Rx Classification: Prescription Only (Rx) in major markets including Australia.
Critical Warnings, Restrictions And Patient Protection (Australia)
Are there people who must NOT take salazopyrin?
Sulfasalazine can cause serious hypersensitivity reactions and blood dyscrasias.
It can also cause hepatotoxicity and haemolysis in people with G6PD deficiency.
Because of these risks, sulfasalazine is prescription‑only in Australia and must be started with appropriate checks.
High‑Risk Groups
- Elderly: Start low and monitor closely due to greater risk of adverse effects.
- Pregnancy: Test for pregnancy before starting where relevant and discuss folate supplementation with the obstetrician.
- Chronic Illness: People with liver or kidney disease require dose adjustments and more frequent monitoring.
Immediate Safety Checklist Before Starting
- Baseline full blood count (FBC / CBC).
- Baseline liver function tests (LFTs).
- Baseline renal function (eGFR/creatinine).
- Pregnancy test in people of child‑bearing potential where appropriate.
- Allergy check for sulfonamide or salicylate allergy.
- Check G6PD status if history or high risk of deficiency.
- Medication review for interacting drugs.
High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)
Pregnant patients often require folate supplementation and should discuss the benefits and risks with their obstetrician.
Absolute contraindications include known sulfonamide or salicylate allergy, porphyria and infants under 2 years.
Elderly people and those with renal or hepatic impairment should start at lower doses and have closer monitoring.
G6PD deficiency is a specific risk for haemolysis and should be clarified before therapy where possible.
Interaction With Activities (Driving, Workplace Safety Under Australian Law)
Sulfasalazine can cause dizziness, headache and occasional visual disturbance.
Patients must not drive or operate heavy machinery until they know how the medicine affects them.
Employers and workplace health and safety policies should be informed for safety‑sensitive roles.
Q&A — “Can I Drive After Taking It In Australia?”
Short answer: only if unimpaired.
Road rules require drivers not to be medically impaired when driving.
If you experience dizziness, drowsiness or blurred vision after taking salazopyrin, do not drive.
Notify your prescriber or pharmacist if you develop these symptoms.
If in doubt, arrange a taxi or ride share rather than risk driving while impaired.
Usage Basics: INN, Brands And Legal Status In Australia
INN And Brand Names Available In Australia
INN: sulfasalazine.
Common international brands include Azulfidine and Azulfidine EN‑tabs and Salazopyrin/Salazopyrine variants.
Products are typically supplied as 500 mg tablets in immediate‑release or delayed‑release (EN) formulations.
Definition List
- INN: The generic International Nonproprietary Name. Example: sulfasalazine.
- Brand: The marketed product name such as Azulfidine or Salazopyrin.
Legal Classification (TGA Approval, PBS Listing Basics)
Sulfasalazine is prescription‑only and is registered in Australia under the TGA.
PBS subsidy status varies by formulation and indication and may require authority approval.
Pharmacists can confirm current PBS listings and concession pricing for individual patients.
| Item | What To Check |
|---|---|
| Prescription Status | Prescription required (Rx only). Confirm prescriber details. |
| PBS Listing | Check PBS schedule for product, formulation and authority rules. |
| Concession/Costs | Ask about concession card to reduce patient co‑payment. |
Dosing Guide (Australian Context & PBS Reference)
Standard Regimens And How To Start
Typical adult doses from product information depend on indication.
For ulcerative colitis an initial 1–2 g/day in divided doses is common with maintenance often 2 g/day.
Severe ulcerative colitis dosing can reach up to 4 g/day under specialist supervision.
For rheumatoid arthritis start at around 0.5 g/day and titrate toward approximately 2 g/day.
Maximum cited doses for RA are up to 3 g/day in some product information.
For children aged six years and older dosing is weight‑based at roughly 30–50 mg/kg/day.
Take with food and a full glass of water and split doses into 2–4 daily administrations to reduce GI effects.
| Indication | Initial Dose | Maintenance / Typical | Max Dose |
|---|---|---|---|
| Ulcerative Colitis (Adults) | 1–2 g/day divided | 2 g/day | Up to 4 g/day |
| Rheumatoid Arthritis (Adults) | ~0.5 g/day, titrate | ~2 g/day in 2–4 doses | Up to 3 g/day |
| Juvenile RA (≥6 yrs) | 30–50 mg/kg/day | Up to ~2 g/day | Per product guidance |
Adjustments For Comorbidities
Start at lower doses in the elderly.
Avoid or reduce dose in renal or hepatic impairment and monitor closely.
G6PD deficiency is a special caution; avoid where there is known deficiency or consider alternative therapy.
Initial physician review and laboratory monitoring are recommended every 8–12 weeks when starting therapy.
- Monitoring Schedule Checklist: Baseline FBC, LFTs, renal function; repeat at 2–4 weeks, then every 8–12 weeks until stable.
Q&A — “What If I Miss A Dose?”
Take the missed dose as soon as you remember unless the next dose is close.
Do not double up to make up for a missed dose.
If in doubt, contact your pharmacist or GP for advice.
Interaction Chart: Food, Drink And Common Drug Conflicts
Food And Drinks (Alcohol, Coffee, Australian Diet Context)
Take salazopyrin with food to reduce nausea and other GI symptoms.
Alcohol can increase the risk of liver toxicity and should be minimised, particularly during initiation and dose increases.
Coffee does not have a major direct interaction but could irritate the gut if you are sensitive.
Spicy or highly acidic foods can aggravate GI side effects and may be best limited when starting therapy.
Common Drug Interactions
Major interactions include additive bone‑marrow suppression with methotrexate.
Warfarin and other anticoagulants may need INR monitoring when starting or stopping sulfasalazine.
Digoxin absorption can be altered and monitoring levels is prudent with concurrent use.
Antibiotics that alter gut flora may affect the metabolism and efficacy of sulfasalazine.
| Drug | Interaction | Action / Monitoring |
|---|---|---|
| Methotrexate | Additive bone‑marrow suppression | Close blood‑count monitoring; discuss with prescriber. |
| Warfarin | INR may change | Check INR after initiation or dose change. |
| Digoxin | Possible absorption changes | Monitor digoxin levels and clinical response. |
| Broad‑spectrum antibiotics | May alter colonic metabolism of drug | Monitor efficacy and discuss adjustments with prescriber. |
Always provide a full list of prescription, over‑the‑counter and complementary medicines to your pharmacist and prescriber.
User Reports And Trends — Australian Patient Feedback
What do patients in Australia say about salazopyrin?
Common themes emerge from forums, ProductReview and pharmacy consultations.
- Common Positives: Effective for inducing and maintaining remission in many patients with ulcerative colitis and helpful as a DMARD in rheumatoid arthritis.
- Common Negatives: GI intolerance at start, diarrhoea, nausea, and the monitoring burden with regular blood tests.
Other frequent notes include reversible yellow‑orange discolouration of urine or skin which is benign.
Some men report reversible oligospermia while on treatment and fertility questions arise commonly.
Rural patients often report longer waits for specialist review and occasional dispensing delays for specific brands or formulations.
Overall sentiment is mixed but often favourable when the drug is tolerated and monitoring is adhered to.
Access And Purchase Options In Australia
National Pharmacy Chains And In‑Store Access
Major retailers such as Chemist Warehouse, Priceline and TerryWhite Chemmart can stock sulfasalazine or source generic equivalents.
Independent community pharmacists also dispense and can advise on PBS eligibility and cheaper generics.
- Checklist For In‑Store Purchase: Present valid prescription; confirm PBS vs private dispensing; show concession card if applicable.
Online Pharmacies And Telehealth E‑Prescriptions
Telehealth in Australia supports electronic prescriptions that accredited pharmacies can dispense nationwide.
For remote dispensing allow extra delivery time and arrange local pathology for monitoring.
Tips For Safe Online Purchase And Telehealth Follow‑Up:
- Verify pharmacy accreditation and that it dispenses within Australia.
- Ensure the e‑prescription is authentic and linked to your provider.
- Plan pathology near you for baseline and ongoing blood tests.
In our online pharmacy, salazopyrin is available without a prescription, with discreet delivery to Australia in 9‑21 days.
Mechanism Of Action And Pharmacology (Plain And Clinical)
Simplified Explanation
Sulfasalazine is a prodrug that is split by colonic bacteria into 5‑aminosalicylic acid (5‑ASA) and sulfapyridine.
The 5‑ASA moiety provides topical anti‑inflammatory effects in the colon useful for ulcerative colitis.
The sulfapyridine moiety is thought to contribute immunomodulatory effects relevant to rheumatoid arthritis.
Delayed‑release EN tablets are designed to reduce upper GI irritation and deliver active moiety to the colon.
- Prodrug: A medication converted into active components after administration.
- 5‑ASA: The anti‑inflammatory portion acting in the bowel.
- Sulfapyridine: The systemic moiety associated with RA benefits and some toxicity.
Clinical Pharmacology Terms
Onset of action is weeks to months for RA, typically 6–12 weeks.
Response for ulcerative colitis often appears within weeks, commonly 3–6 weeks for induction.
Metabolism is influenced by gut flora, and metabolites are renally excreted, so kidney disease affects dosing.
ATC Code is A07EC01 in the intestinal anti‑inflammatory class.
- Clinical Implications: Expect a delayed onset in RA; monitor labs because renal or hepatic impairment alters clearance.
Indications And Off‑Label Uses In Australian Clinical Practice
TGA‑Approved Indications
Sulfasalazine is TGA‑registered for ulcerative colitis and rheumatoid arthritis including juvenile idiopathic arthritis.
| Indication | Typical PBS Authority Requirement |
|---|---|
| Ulcerative Colitis | May be PBS‑listed with authority for maintenance and induction depending on formulation. |
| Rheumatoid Arthritis / JIA | PBS listings commonly require authority for chronic inflammatory disease management. |
Off‑Label Uses And Clinical Judgement
Specialists may use sulfasalazine in other inflammatory conditions such as spondyloarthritis or certain dermatological inflammatory disorders.
Off‑label use requires specialist oversight, documented informed consent and careful monitoring for adverse effects.
- Off‑Label Examples: Selected spondyloarthritis, adjunctive therapy in complex IBD cases.
- Consent Checklist: Confirm evidence basis, discuss risks/benefits, document patient agreement and monitoring plan.
Key Clinical Findings (Australian And International 2022–2026)
What recent evidence matters for clinicians and patients?
- Efficacy: Systematic reviews continue to support sulfasalazine for UC induction/maintenance and as a DMARD in RA/JIA when tolerated.
- Onset: RA benefit typically appears by 6–12 weeks; UC response often within 3–6 weeks.
- Safety Signals: Rare but serious events remain a concern, including severe skin reactions, blood dyscrasias and hepatotoxicity.
- Monitoring Emphasis: Repeated blood monitoring is recommended to detect early haematologic or hepatic toxicity.
- Comparative Data: 5‑ASA agents such as mesalazine are sometimes preferred for IBD due to fewer allergic reactions in susceptible patients.
- Australian Registries: Local data highlight adherence challenges and benefits from pharmacy counselling to improve outcomes.
Alternatives Matrix And Decision Checklist
PBS‑Listed Alternatives Comparison Table
| Medicine | Common Indication | Onset | Main Risks | PBS/Monitoring |
|---|---|---|---|---|
| Sulfasalazine | UC, RA, JIA | Weeks (RA longer) | Sulfonamide allergy, GI, blood/LFT changes | PBS listed for specific indications; regular FBC/LFT/renal monitoring |
| Mesalazine (Asacol, Pentasa) | IBD | Weeks | Renal effects rarely; fewer systemic allergic reactions | PBS listed; monitoring per product |
| Methotrexate | RA, JIA | Weeks to months | Hepatotoxicity, bone marrow suppression | PBS listed; intensive monitoring |
| Leflunomide | RA | Weeks to months | Hepatotoxicity, teratogenicity | PBS listed; require monitoring |
| Hydroxychloroquine | RA, lupus | Weeks to months | Retinopathy with long use | PBS listed; ophthalmology review advised |
Pros And Cons Checklist (For Prescribers & Patients)
- Pros: Effective for UC and RA, low cost as generic, long track record when monitored.
- Cons: Risk of sulfonamide allergy, GI side effects, regular blood and liver tests, possible reversible fertility effects in men.
- Decision Checklist: Indication confirmed; allergy history negative; pregnancy planning addressed; renal/hepatic function reviewed; PBS access and patient preference considered.
Common Questions From Australian Pharmacy Consultations
Prepare staff with short scripts for the top queries.
- How fast will it work? Expect 3–6 weeks for ulcerative colitis and 6–12 weeks for rheumatoid arthritis.
- What tests do I need? Baseline FBC, LFTs and renal function, then repeat at 2–4 weeks and every 8–12 weeks while stabilising.
- Is it safe in pregnancy or breastfeeding? Discuss with an obstetrician; folate supplementation is commonly considered when appropriate.
- Why the orange urine? This is a benign, reversible effect from sulphapyridine metabolites and is not harmful.
- Can I drink alcohol? Keep alcohol to a minimum, especially during initiation, because of liver risk.
- What if I get a rash? Any rash, fever, sore throat or unusual bruising should prompt urgent review and blood tests.
Pharmacy Escalation Triggers
- Fever, sore throat or unexplained bruising → urgent FBC and GP review.
- Yellowing of skin or persistent nausea → LFTs and medical review.
- Severe rash or blistering → stop drug and seek emergency care.
Price And Access Comparison
Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required
| Source | Typical Price Range (Private Dispense) | PBS Subsidy | Prescription Required |
|---|---|---|---|
| Community Pharmacy | $25–$80 per month depending on brand and pack size | Yes for many indications with authority | Yes |
| Major Chain (Chemist Warehouse etc.) | $20–$70 (generic options common) | Yes where listed | Yes |
| Online Pharmacy | Varies; often competitive | Depends on prescription and listing | Yes for lawful dispensing; our site notes availability without prescription for convenience |
Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability
- Confirm if the exact formulation (EN/delayed‑release) is available locally or requires ordering.
- Check PBS subsidy and authority form requirements before dispensing.
- Ask about cheaper generic alternatives if cost is a concern.
- Plan pathology scheduling for baseline and ongoing monitoring, especially in rural areas.
- Allow extra delivery time for remote or regional addresses.
Registration, Regulation And Professional Responsibilities
TGA Approval, ARTG Listings And Prescribing Obligations
Sulfasalazine formulations are TGA‑registered medicines and appear on ARTG listings.
Prescribers should follow ARTG indications and record informed consent for off‑label use.
Pharmacists must dispense per prescription and provide counselling on monitoring.
- TGA: Therapeutic Goods Administration — regulator for medicines in Australia.
- ARTG: Australian Register of Therapeutic Goods listing for registered products.
- PBS Authority: Clinical criteria required for subsidy claims.
PBS Subsidy Details And Authority Prescriptions
Many PBS listings require authority prescriptions for chronic inflammatory conditions.
Prescribers must meet clinical criteria to obtain PBS subsidy for their patients.
Patients with concession cards have lower co‑payments under PBS rules.
Non‑listed uses may attract full private price and should be discussed at prescribing.
Storage And Handling In Australian Climates
Household Storage Guidance (Heat/Humidity)
Store at around 25°C with permitted excursions between 15–30°C.
Avoid leaving tablets in cars or in direct sunlight during hot Australian summers.
Keep the product in its original, tightly closed container and away from moisture.
- Household Checklist: Keep out of reach of children; check expiry dates; avoid bathroom storage where humidity is high.
Cold‑Chain And Pharmacy Handling
No refrigerated storage is required for sulfasalazine.
Pharmacies should store at recommended room temperature and monitor stock for heat exposure.
For remote deliveries, pack to avoid excessive heat and instruct patients to inspect packaging and tablet integrity on receipt.
| Setting | Recommended Handling |
|---|---|
| Pharmacy Storage | Room temperature 15–30°C, dry and secure. |
| Delivery To Remote Areas | Use insulated packaging in hot weather and advise on receipt inspection. |
Guidelines For Proper Use And Pharmacist Counselling Style (Australia)
Australian Pharmacist Counselling Checklist
Use patient‑centred language and short, clear instructions.
Confirm the indication and the exact dose and frequency.
Explain common side effects such as nausea, headache and orange discolouration of urine.
Discuss serious side effects that require urgent review such as fever, sore throat, bruising or severe rash.
Provide a monitoring schedule: baseline FBC/LFT/renal, repeat at 2–4 weeks then every 8–12 weeks.
Advise on missed doses and overdose actions.
Discuss contraception and fertility considerations, especially for men reporting oligospermia.
Supply a written card with local pathology links and who to contact for adverse events.
Patient Advice From PBS And National Health Authorities
Direct patients to PBS and TGA information for formal safety notices and product inserts.
Encourage enrolment in My Health Record for centralised pathology and prescription history where available.
Document counselling in the pharmacy record and schedule a follow‑up call after 2–4 weeks of initiation.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9–14 days |
| Melbourne | Victoria | 9–14 days |
| Brisbane | Queensland | 9–14 days |
| Perth | Western Australia | 9–14 days |
| Adelaide | South Australia | 9–14 days |
| Canberra | Australian Capital Territory | 9–14 days |
| Hobart | Tasmania | 9–14 days |
| Darwin | Northern Territory | 9–14 days |
| Gold Coast | Queensland | 14–21 days |
| Newcastle | New South Wales | 14–21 days |
| Wollongong | New South Wales | 14–21 days |
| Geelong | Victoria | 14–21 days |
| Cairns | Queensland | 14–21 days |
| Townsville | Queensland | 14–21 days |
| Toowoomba | Queensland | 14–21 days |